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Abstract
Background:  Methylphenidate (MPH) is commonly prescribed in the treatment of Attention-Deficit/
Hyperactivity Disorder or ADHD. Concerta and Metadate CD are once-daily formulations of MPH using different
delivery mechanisms resulting in different pharmacokinetic profiles. A recent study (COMACS) showed that for
near-milligram (mg) equivalent daily doses, Metadate CD provides greater symptom control in the morning (1.5
through 4.5 hours post-dose), while Concerta provides greater control in the early evening (12 hours post-dose).
Non-inferential comparison of effects for different dose levels of the two formulations suggested that equivalent
levels of morning symptom control could be obtained with lower daily doses of Metadate CD than Concerta; the
situation being reversed in the evening. The current paper presents a secondary analysis that provides a statistical
test of these observations.
Method: The COMACS study was a multi-center, double-blind crossover study of Metadate CD, Concerta and
placebo with each treatment administered for 1 week. Children were assigned on the basis of their pre-trial
dosage to either high (Metadate CD 60 mg; Concerta 54 mg), medium (Metadate CD 40 mg; Concerta 36 mg)
or low doses (Metadate CD 20 mg; Concerta 18 mg) of MPH, and attended a laboratory school on the 7th day
for assessment at 7 sessions across the day. For the post-hoc comparisons across dose levels presented here, total
SKAMP scores with the active treatments (adjusted for placebo response) were analyzed using an analysis of
covariance, with a combined measure modeling placebo response across all time period as the covariate.
Results: Symptom control from 1.5 through 6.0 hours post-dose was as good with lower doses of Metadate CD
(20 and 40 mg) as with higher doses of Concerta (36 and 54 mg, respectively). Lower daily doses of Concerta (18
and 36 mg) and higher doses of Metadate CD (40 and 60 mg, respectively) gave equivalent control at 7.5 and 12
hours with Metadate CD giving better control from1.5 through 6.0 hours post-dose.
Conclusions: Different delivery profiles of Metadate CD and Concerta can be exploited to limit total daily
exposure to MPH while at the same targeting a specific, especially clinically significant, period of the day. These
results need to be confirmed in a study in which children are randomly allocated to different dose levels of the
two formulations and plasma MPH concentrations are assessed simultaneously.
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Background
Attention Deficit /Hyperactivity Disorder (ADHD) is a rel-
atively common early onset developmental condition
characterised by a pervasive and persistent pattern of age
inappropriate and debilitating inattention, impulsiveness
and overactivity. It is reported to affect between 3 and 6
percent of the childhood population and, if untreated, to
be associated with a poor prognosis in adolescence and
adulthood [1,2]. Methylphenidate (MPH) remains a
pharmacological treatment of first choice for children
with ADHD [3]. Historically, effective 'all-day' manage-
ment of symptoms has relied on the use of multiple doses
(typically two or three) of immediate release (IR) MPH
spread out across the day (early morning, midday and
evening)[4]. The use of IR formulations in this way com-
bines all-day coverage with the opportunity to tailor doses
at different times of the day to meet the specific needs of
children. However, there is evidence that multiple dosing
leads to problems with adherence especially during the
school day where children receiving medication may feel
stigmatised by their classmates [5]. Once-a-day sustained
release (SR) formulations have been licensed in the US for
some time but the early formulations were not widely
used because of the perceived lack of efficacy especially
with regard to speed of onset [6]. In the last few years a
second generation of more effective formulations
(referred to here as extended release formulations – ER)
have been licensed. These exploit a range of different
delivery technologies and offer smooth patterns of symp-
tom control across the day [7-9]. These new formulations
represent a major advance in the clinical management of
the condition and are popular with both patients and cli-
nicians. Various ER formulations have been designed each
with a different pharmacokinetic (PK) and pharmacody-
namic (PD) profile that results in differing patterns of
duration and timing of effect. Thus they have the potential
to provide clinicians with the opportunity to simplify the
dosing regime without loosing the ability to tailor treat-
ment to the clinical profile of an individual patient. In
order to exploit this opportunity clinicians need to be able
to make informed decisions about the comparative bene-
fits of differing doses of different formulations with differ-
ent PK/PD profiles. Unfortunately, to date, there have
been few head-to-head trials of these new ER formula-
tions that provide the information required for this.
We recently reported the results of a randomised, placebo-
controlled, head-to-head comparison of the pharmacody-
namic (PD) properties of near mg-equivalent daily doses
of two safe and effective [10,11] ER formulations of MPH
in children (the COMACS study; [12]). Concerta (CON)
was designed to replace three-times-a-day (TID) IR MPH
and provide twelve-hour symptom coverage. It consists of
an insoluble OROS™ tablet with an IR drug over coat.
Twenty two percent of the dose is in the IR overcoat and
78% in the ER core, which is released, by an osmotic
pump process [7,10]. Metadate CD (MCD) has a profile
more in keeping with a two-times-a-day (BID) regime of
IR MPH. It consists of a soluble capsule containing a mix-
ture of IR MPH beads (30% of the total dose) and ER MPH
beads coated with a controlled-release polymer to deliver
MPH gradually over the extended period (70% of the total
dose) [8,11]. Low (20 mg MCD and 18 mg CON),
medium (40 mg MCD and 36 mg CON), and high (60 mg
MCD and 54 mg CON) doses are available for each for-
mulation and have been demonstrated to deliver equiva-
lent levels of total exposure to MPH in adults [13] (as
shown by comparable AUCs and Cmax). Recently a 10 and
30 mg dose of MCD and a 27 mg dose of CON were
licensed, but these were not available during the
COMACS study. As a result of the design differences, MCD
releases 50% more IR MPH in the initial bolus delivery
process than CON for a near mg-equivalent total daily
doses. Furthermore although the amount of ER MPH is
the same for near mg-equivalent doses the pattern of
delivery differs with MPH release front-loaded with MCD
(starting at 1 hour) and more back-loaded with CON.
The different IR/ER ratios and time-course for dissolution
of the two extended-release portions of the formulations
result in distinctly different plasma concentration vs. time
profiles in adults when compared at near-mg equivalent
total doses [13]. Concentrations of MPH are significantly
higher for MCD than for CON for up to 6 hours after dos-
ing, and, by contrast, concentrations of MPH are signifi-
cantly higher for CON from 8 through 12 hrs after dosing.
Differences in plasma concentration vs. time profiles are
expected to occur in children as the PK of MPH in adults
and children are qualitatively similar (i.e. there are no
reported age-related differences in absorption, distribu-
tion, metabolism and excretion of MPH between these
populations [14-16]). In agreement, the plasma concen-
tration vs. time profile for MCD in children is consistent
with that observed in adults [8]. Results of the COMACS
study demonstrated that the PD patterns of the two for-
mulations in children mirrored their expected differences
in plasma concentration vs. time profiles. This meant that
at each of the three near-mg equivalent daily dose levels,
MCD produced a greater reduction in symptoms during
the morning (up to six hours from drug administration)
while CON produced superior control in the early evening
(i.e., at 12 hours post-dose). However, the two formula-
tions were equivalent in their effects during the afternoon
between 6 and 7.5 hours post dose [12].
The publication of the main analysis of the COMACS
study data has led to a number of suggestions for alterna-
tive analyses that would usefully address questions of the
clinical utility of the two formulations. Although from a
scientific point of view the aim of the COMACS study – toBMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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compare across-the-day PD profiles of the two formula-
tions – was best served by a comparison of bio-equivalent
(i.e. AUC-equivalent) total daily doses, other strategies for
selecting comparator doses could have been legitimately
followed. For instance, it has been suggested that compa-
rators could have been matched on the basis of the size of
the IR component dose rather than the total daily dose
(see Table 1 for IR and ER components of the MCD and
CON). In this regard it is interesting that an informal com-
parison of the relative efficacy of MCD and CON at each
dose level suggested that equivalent morning symptom
control would possibly be obtained at doses with a near
mg-equivalent IR component but with a lower total daily
dose of MCD than CON, while the situation was reversed
in the evening (that is, lower daily doses of CON could
have equivalent efficacy to higher doses of MCD). In each
case, the COMACS study data suggested that this targeted
control would be gained at the cost of efficacy at other
point(s) during the day. These across-the-day-changes in
patterns of the relative efficacy of the two formulations are
consistent with what would be expected on the basis of
their IR/ER ratios, their drug delivery mechanisms, and
their resulting predicted plasma concentration vs. time
profiles.
These observations could be clinically important because
it is expected that patients and their families may be will-
ing to trade some degree of symptom control at certain
times of the day if that allows them to reduce the overall
dose of MPH. In such cases, clinicians will seek a dosing
profile that allows them to target a specific period of the
day that is especially important for a particular patient. By
doing this they can retain the effectiveness of a higher
dose component during these selected periods of the day
while limiting total daily MPH exposure. For instance, in
some cases clinicians, patients and parents may seek
symptom control in the evening while being less con-
cerned about the daytime. In other cases they may wish to
focus on morning and afternoon symptom control.
Because the main aim of the COMACS study design was
to compare the PD profiles of MCD and CON across the
day, initial analyses were limited to within-subject com-
parisons between equivalent total daily doses (low,
medium and high) of the formulations. Thus this primary
analysis of the data did not include a cross-dose analysis,
which would allow the relative efficacy of different daily
doses of MCD and CON to be directly tested at different
times of the day. The present paper presents a statistical
cross-dose analysis of the efficacy of MCD and CON at dif-
ferent times of the day in order to test these observations
directly.
The ideal way to test across-dose comparisons of different
medications is to randomise patients to different dosing
strata. In the COMACS study children were assigned to
dosing strata on the basis of pre-trial dose levels. How-
ever, because the COMACS study was designed to have
similar and substantial numbers of children in each dos-
ing strata the data set still offers the opportunity for a pre-
liminary  post-hoc  exploration of the PD profiles of
different doses of MCD and CON. Furthermore, the inclu-
sion of the placebo arm in the COMACS design enabled
us to directly address one of the possible major confounds
associated with across dose comparisons in this sort of
stratified design. An inspection of the published COMACS
data revealed that the placebo scores measured at different
sessions across the day were higher in the high dose
group, than the medium or low dose groups. This suggests
that children on higher doses may have had a more severe
expression of the disorder making cross-group compari-
sons complicated. In the analysis reported in the current
paper these placebo scores were used to adjust the treat-
ment outcome scores to take account of this.
A number of specific across-dose comparisons were made.
First, the lower daily doses (20 mg and 40 mg) of MCD
were compared to the higher daily doses of CON (36 mg
and 54 mg respectively). The comparison between MCD
20 mg and CON 36 mg is of particular interest to
clinicians as these are the suggested dose substitutions for
IR MPH 10 mg BID and 10 mg TID, respectively. On the
basis of the initial observations of the COMACS study it
was predicted that MCD 20 and CON 36 mg, and MCD 40
and CON 54 mg would produce equivalent control in the
morning (from 1.5 through 4.5 hours post-dose). In con-
trast, at these dose levels it was predicted that CON would
produce significantly greater effect as the day wore on
(from 6 hours onwards). Second, lower daily doses (18
mg and 36 mg) of CON were compared with higher doses
of MCD (40 mg and 60 mg respectively). We tested the
prediction that at these dosing levels MCD would demon-
Table 1: Amounts of Immediate-Release (IR) and Extended-
Release (ER) Methylphenidate in Available Dosage forms of 
Metadate CD and Concertaa
IR MPH ER MPH
18 mg CON 4 mg 14 mg
20 mg MCD 6 mg 14 mg
36 mg CON 8 mg 28 mg
40 mg MCD (2 × 20 mg capsules) 12 mg 28 mg
54 mg CON 12 mg 42 mg
60 mg MCD (3 × 20 mg capsules) 18 mg 42 mg
aRecently, a 10- and 30-mg dose strength of Metadate CD and a 27-mg 
dose strength of Concerta have become available. These were not available 
at the time of the COMACS study.BMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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strate greater efficacy only in the morning and early after-
noon (from 1.5 through 6 hours); so that despite the
lower total daily dosing levels, CON, designed to be effec-
tive over a 12 hour period, would still be more effective
than MCD, designed to be effective over an 8 hour period,
at reducing symptoms in the early evening (i.e., at 12
hours).
Methods
Clinical materials
Metadate® CD (methylphenidate HCl, USP) Extended-
Release Capsules (MCD) were obtained from Eurand
Americas, Inc (Vandalia, OH), while Concerta® (methyl-
phenidate HCl) Extended-release Tablets (CON) were
obtained from Alza Corporation (Mountain View, CA).
For a detailed description of the preparation of clinical
materials see Swanson et al., 2004 [12].
Patients
Six to 12 year old children, with interview-confirmed-
diagnoses of ADHD who were being treated with MPH in
doses of between 10 to 60 mg/day (5 mg to 20 mg per
administration, one to three times a day) were recruited
for the trial. Children were deemed otherwise healthy on
the basis of an extensive medical history and physical
examination. Children were excluded if they had an IQ
below 80 or the inability to follow or understand study
instructions. Other standard exclusion criteria for MPH
drug trials applied [12]. Children provided signed assent,
and their legal guardians signed an IRB-approved consent
form. A total of 214 patients were screened for participa-
tion into the study and 184 patients (74 percent of which
were male) were stratified across the three dose levels
based on their previously established clinical doses of
MPH. Eighty-two percent of the patients met the criteria
for ADHD-Combined Type with a further 15 percent
meeting the criteria for Inattentive Type. Approximately
25% of children had a co-morbid condition (e.g., anxiety
and oppositional defiant disorder). At prescreening,
approximately 91% of the patients were on once-a-day
dosing regimens. Of the remainder 7.6% were taking BID
and 1.6% TID IR MPH. Of the 184 subjects entering the
study, 157 received all three levels of treatment and partic-
ipated in all seven classroom sessions. The demographic
characteristics of the sample of patients that completed all
three treatments (n = 157) were not different than those
reported for the full sample.
Design
This was a ten-site, double-blind, placebo-controlled
crossover study comparing three treatment conditions:
MCD, CON, and placebo (PLA). The study was conducted
in accordance with the principle of the Declaration of Hel-
sinki and its amendments and the International Commit-
tee on Harmonization Guidelines on Good Clinical
Practice. Dose-level assignment was made according to
pre-existing daily dosing requirement for MPH and chil-
dren remained at the dose-level assigned for the entire
study duration. Children treated with low doses (≤ 15 mg/
day IR or 20 mg/day ER) of MPH were randomized to
receive a daily dose of MCD 20 mg, CON 18 mg or PLA;
those treated with medium doses (>10 to ≤ 30 mg/day IR
or >20 to ≤ 40 mg/day ER) of MPH were randomized to
receive MCD 40 mg, CON 36 mg or PLA; and children
treated with high doses (> 30 mg/day IR or >40 mg/day
ER) of MPH were randomized to receive MCD 60 mg,
CON 54 mg, or PLA. Each of the three treatments was
administered for 7 days (in randomized order) without an
intervening washout period. Assessments took place in
the laboratory school on Days 7, 14, and 21 (for a detailed
description of the laboratory classroom day see Swanson
et al., 2004 [12]). Two trained observers assessed patients
during each classroom session on the Swanson, Kotkin,
Atkins, M/Flynn, Pelham Scale (SKAMP; [17,18]) on the
basis of a 1.5-hour cycle of activities with separate assess-
ments of Attention and Deportment being made at 0, 1.5,
3.0, 4.5, 6.0, 7.5 and then 12 hours after drug administra-
tion. Because Attention and Deportment scores were
highly correlated in the original COMACS analysis, these
subscales were combined in the current analysis for ease
of presentation.
Statistical analyses
A preliminary factorial Analysis of Variance (ANOVA)
using the SPSS General Linear Model was conducted in
order to confirm that the pattern of effects of Treatment
(CON, MCD, PLA), Dose (low, med, high) and Session
(0, 1.5, 3.0, 4.5, 6, 7.5 and 12 hours) found in the Swan-
son et al. (2004) paper [12] held when the individual
SKAMP Attention and Deportment scales were combined
to provide a composite score. In order to test the specific
across-dose predictions Analysis of Covariance
(ANCOVA) was used to make the four comparisons out-
lined above. In each case, Treatment/Dose (analysis 1-
MCD 20 mg vs. CON 36 mg; analysis 2-MCD 40 mg vs.
CON 54 mg; analysis 3-MCD 40 mg vs. CON 18 mg; anal-
ysis 4-MCD 60 mg vs. CON 36 mg) was the between-sub-
jects independent factor. Session was the within- subject
factor, and the dependent variable was total SKAMP score.
Children's active drug SKAMP scores were adjusted to take
account of their behaviour on PLA using a weighted com-
bined SKAMP score for all observation points. Weighting
was determined by principle components analysis and
was similar for each observation point. Other between-
subjects factors included in the initial COMACS study
data analysis (including Site and Sequence of Drugs) were
excluded from the current analysis. The GLM option that
utilizes data from just those subjects with complete data
(i.e., those cases without missing data) was selected for
each separate analysis.BMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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Results
Preliminary analysis
Table 2 shows the total SKAMP scores for each observa-
tion sessions at each dose level of CON, MCD and pla-
cebo. There were significant main effects of treatment, F
(2, 306) = 92.06; p < 0.001, and session, F (6, 918) =
34.70; p < 0.001, and an interaction between treatment
and session, F (12, 1836) = 45.21; p < 0.001. Planned
comparisons demonstrated that the relative efficacy of the
two formulations in relation to PLA was as described by
Swanson et al. [12] for separate SKAMP deportment and
attention scales: CON = MCD < PLA at the time of dose
delivery, MCD > CON > PLA for 1.5, 3 and 4.5 hours,
MCD = CON > PLA for session 6 and 7.5 hours and MCD
= PLA < CON at 12 hours. For a discussion on the superi-
ority of placebo immediately after dosing, the reader is
referred to Swanson et al [12].
Comparison across dose levels
The PLA adjusted scores for the total SKAMP score relating
to the specific cross-dose comparisons are presented in
Figures 1a through 1d. The number of patients included in
specific analysis were as follows: MCD 20 vs. CON 36 – 58
vs. 53; MCD 40 vs. CON 54 – 55 vs. 47; MCD 40 vs. CON
18 – 55 vs. 57; and MCD 60 vs. CON 36 – 49 vs. 53.
Lower daily doses of MCD than CON
The comparison of MCD 20 mg and CON 36 mg revealed
no overall difference between treatments, F (1,108) =
0.001; ns. There was an effect of session, F (6,648) =
15.08; p < 0.001 and an interaction between treatment
and session F (6,648) = 3.98; p < 0.01. The two treatments
did not differ at the time of dose administration or 3, 4.5,
6 and 7.5 hours after it (Fs < 2.5). MCD was superior to
CON at 1.5 hours, F (2, 110) = 4.48; p < 0.05, while CON
was superior to MCD at 12 hours, F (2,109) = 3.94; p <
0.05. The comparison of MCD 40 mg and CON 54 mg
revealed no overall difference between treatments, F
(1,99) = 1.05; ns. There was an effect of session F (6,594)
= 36.20; p < 0.001 and an interaction between treatment
and session, F (6,594) = 3.72; p < 0.01. There was no dif-
ference between treatments at the time of administration
or at 1.5, 3, 4.5 and 6 hours (Fs < 3.58; ns). However,
CON was superior to MCD at 7.5, F (1,100) = 6.26; p <
0.05, and 12 hours, F (1,99) = 4.55; p < 0.05.
Lower daily dose of CON than MCD
For the comparison of MCD 40 mg and CON 18 mg there
was a main effect of treatment with MCD being associated
with lower (i.e., better) SKAMP scores than CON,
F(1,109) = 6.50, p < 0.05. There was also an effect of ses-
sion, F(6,654) = 18.61, p < 0.001 and an interaction
between treatment and session, F(6,654) = 8.32; p <
0.001. MCD gave lower (better) scores at 1.5 (F(1,111) =
10.02; p < 0.005), 3 (F(1,110) = 18.36; p < 0.001), 4.5
(F(1,111) = 16.16; p < 0.001), and 6 (F(2,111) = 5.94; p
< 0.05) hours. However, there was no difference between
the two formulations at 7.5 and 12 hours, Fs < 2.75. MCD
60 mg also gave significantly lower scores than CON 36, F
(1,99) = 14.03; p < 0.001. Once again there was an effect
of session, F (6,594) = 35.38; p < 0.001, and an interac-
tion between treatment and session, F (6,594) = 10.55; p
< 0.001. MCD gave significantly lower scores at 1.5 (F
(1,100) = 35.01; p < 0.001), 3 (F (1,100) = 30.99; p <
0.001), 4.5 (F (1,99) = 18.23; p < 0.001) and 6 (F (1,100)
= 9.66; p < 0.005) hours but not at 7.5 and 12 hours, Fs <
0.55.
Discussion
CON and MCD are once-daily formulations of MPH
using different drug delivery mechanisms resulting in dif-
ferent plasma concentration vs. time profiles in both
adults [13] and children [8]. In the COMACS study we
compared the PD profiles of equivalent daily doses of the
two formulations in children with ADHD [12]. The pri-
mary analysis was restricted to a comparison of the rela-
tive efficacy of the two formulations within subjects and
dosing strata (i.e., across AUC-equivalent total daily
doses). As predicted by the PK-PD model proposed by
Swanson [19], MCD provided greater symptom control in
Table 2: Mean (± SD) SKAMP Total Scores at Each Observation Session for Each Treatment at Each Dose Levela
MCD CON PLA
Observation 
Session (hrs)
Low Med High Low Med High Low Med High
0 18.48 (11.82) 20.88 (12.95) 19.91 (13.15) 18.04 (10.13) 19.14 (12.14) 21.47 (13.06) 13.58 (9.72) 16.02 (11.84) 13.96 (11.14)
1.5 11.44 (7.99) 10.98 (8.62) 6.55 (5.85) 14.04 (9.85) 14.86 (12.01) 11.34 (9.71) 19.10 (12.83) 19.47 (12.56) 18.88 (13.48)
3.0 12.57 (9.92) 11.03 (9.66) 7.31 (6.10) 16.44 (12.43) 15.29 (12.72) 12.62 (11.00) 21.47 (14.61) 20.98 (14.11) 22.11 (14.10)
4.5 13.46 (11.53) 12.39 (10.32) 9.15 (8.62) 17.55 (13.37) 15.09 (12.60) 13.55 (11.91) 20.23 (11.92) 22.09 (15.46) 23.44 (12.55)
6.0 16.08 (13.27) 14.47 (11.53) 10.30 (9.71) 17.00 (12.12) 14.28 (11.73) 12.04 (11.62) 22.98 (12.79) 22.15 (13.91) 26.02 (14.56)
7.5 15.85 (11.21) 17.26 (13.63) 14.29 (12.55) 18.62 (12.66) 15.19 (13.47) 13.47 (12.97) 23.54 (12.96) 23.13 (14.72) 24.48 (14.68)
12.0 20.44 (13.75) 20.28 (15.02 19.85 (14.41) 16.90 (13.36) 17.81 (13.84) 16.74 (14.98) 19.45 (13.46) 20.73 (13.46) 22.02 (15.17)
aLower SKAMP scores indicate greater efficacy
CON = Concerta; MCD = Metadate CD; PLA = placebo. Low = Low Dose (CON 18 mg; MCD 20 mg), Med = Medium Dose (CON 36 mg; MCD 40 mg), Hi = High Dose (CON 54 mg ; 
MCD 60 mg).BMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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the morning (from 1.5 through 4.5 hours post-dose),
while CON gave greater control in the early evening (at 12
hours post-dose). However, on the basis of the IR/ER
ratios of the two formulations, the expected plasma con-
centration vs. time profiles, and the informal observation
of the relative efficacy of the different formulations made
between subjects across dosing levels in the COMACS
study, it was predicted that a lower total daily dose of
MCD (i.e., 20 and 40 mg) would give equal levels of
symptom control in the morning when compared to CON
at the next highest dosing strata (i.e., 36 and 54 mg); the
situation being reversed for CON in the later part of the
afternoon and in the evening. Specifically, it was predicted
that MCD 20 mg and 40 mg would give similar levels of
symptom control to that provided by CON 36 mg and 54
mg, respectively, from 1.5 through 4.5 hours post dose.
This would reflect the fifty percent higher relative propor-
tion of IR delivery in MCD compared to CON. In contrast,
the higher ER doses of CON would give significantly bet-
ter control between 6 and 12 hours.
There was only partial support for these predictions. Not
only was there no significant difference between placebo
adjusted total SKAMP scores for MCD 40 mg and CON 54
mg from 1.5 through 4.5 hours, but also at 6.0 hours post-
dose. In addition, comparison at the lower dose levels
(MCD 20 mg and CON 36 mg) gave a surprising result:
MCD appeared to be associated with a stronger effect and
a more rapid onset of action than CON during the very
early period post-dose. This was indicated both by the
absolute values (i.e., the intercept) for the two formula-
tions at 1.5 hours post-dose and the steeper slopes for
Mean (± SE) of placebo-adjusted total SKAMP scores for each comparison Figure 1
Mean (± SE) of placebo-adjusted total SKAMP scores for each comparison. Lower SKAMP scores indicate greater 
efficacy. Asterisks indicate MCD was significantly better than CON (p < 0.05) while crosses indicate CON was significantly bet-
ter than MCD (p < 0.05).BMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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MCD than CON between 0 and 1.5 hours. This was a par-
ticularly unexpected finding because at the dose levels
being compared, MPH available from the IR component
of MCD (6 mg) was less than that available for CON (8
mg). Given that the active drug is the same in the two for-
mulations and assuming that clinical efficacy reflects
MPH serum concentrations as has been proposed by
Swanson [19] this would suggest that non-drug related
factors may be involved. Non-drug factors may include
those associated with the speed of dissolution and absorp-
tion associated with the different delivery mechanisms of
the two formulations. For instance, it may be that the IR
beads of MCD are associated with a higher rate of dissolu-
tion than the CON MPH overcoat, although there is no
reason to expect this. Alternatively, the rate of dissolution
of the IR components of the two formulations may be
equivalent but the distinction between the IR and ER com-
ponents may be less clear-cut in MCD than CON. This
would produce early exposure to MPH from some ER
beads in addition to IR beads during the early part of the
day. Dissolution studies support this by suggesting that
while the ER components of MCD and CON both start to
release MPH at approximately 1 hour post-dose, the MCD
ER MPH component seems to be more front-end loaded,
while CON's ER MPH component seems to be more back-
end loaded. MCD drug delivery technology, may there-
fore, be more efficient at delivering IR components at low
doses, and this requires further investigation.
The predictions relating to the efficacy of these different
dose comparisons during the latter part of the day were
confirmed only at the 12 hour testing session for the lower
doses (CON 36 mg vs. MCD 20 mg) and the 7.5 and 12
hours sessions for the higher doses (CON 54 mg vs. MCD
40 mg). Given their expected plasma concentration vs.
time profiles in children, one would expect greater efficacy
from CON than MCD whatever the dose comparison
being made. The 7.5 hour post-dose period is less clear-cut
in terms of the relative benefit of the two formulations.
The second set of predictions related to the value of lower
daily doses of CON (18 mg and 36 mg) to provide equiv-
alent symptom coverage compared to higher doses of
MCD (40 mg and 60 mg, respectively) in the late after-
noon and superior coverage in the evening. The predic-
tions for late afternoon were supported at both the higher
and lower cross-dose comparisons with lower doses of
CON giving equivalent control at 7.5 hours. However,
interestingly, at 12 hours the higher doses of MCD
remained equivalent to CON. This result is in keeping
with the idea, supported by the expected plasma concen-
tration and known dissolution data that MCD continues
to release MPH up to 12 hours post-dose. As expected, the
higher doses of MCD had a greater effect between dosing
through 6 hours post dose.
Given design limitations it is possible that these effects are
not 'real' effects related to dose and treatment type but are
related to differences between the types of children
assigned to different dose levels. The way in which the
children were assigned to dose level meant that across-
dose comparisons of different treatments could be subject
to a number of confounds. First, it could be that children
were placed on higher doses because they had a more
severe form of ADHD. In the present study we attempted
to deal with the possible confounds that such an approach
to dose assignment might bring by using the placebo
SKAMP score (across all time periods) as a covariate. This
score was included as a proxy for severity of ADHD in
order to control for the possibility that children assigned
to the higher-dose level had a more severe form of the
condition.
A second possible confound, not corrected for by control-
ling for placebo scores, relates to the child's sensitivity to
MPH: Children may have been prescribed higher pre-
study doses of MPH because they were less sensitive to
MPH and did not respond to the lower dose. Such
variations in sensitivity could be independent of overall
severity of the disorder and therefore constitute a second
possible confound. If this were the case then an across-
dose comparison would be between more- and less-sensi-
tive children. There are two pieces of evidence that argue
against this as an explanation for the current results. First,
Swanson et al. [12] reported that the between-subject fac-
tor of dose was significant on SKAMP Attention scores in
the COMACS study. If dose levels were determined by
MPH sensitivity such an effect would not have been
expected. Second, there is no reason to believe that sensi-
tivity to MPH should favor one formulation at one time
(i.e., MCD in the morning) and the second formulation at
another time (i.e., CON in the evening). Differential MPH
sensitivity, therefore, seems an unlikely explanation for
the current pattern of results. It is also possible that basing
the study dose level on pre-study total daily dose may
have had differential effects for children receiving TID and
BID doses of IR preparations prior to the study. Children
on, for instance, two tablets of 10 mg IR given early in the
morning and then in the afternoon would be assigned to
the low dose strata of 18 mg of CON thought to be equiv-
alent to 5 mg IR tablets taken TID. In this case, children,
although receiving AUC-equivalent daily doses, would be
receiving a lower morning (5 mg rather 10 mg) and after-
noon dose (5 mg rather 10 mg) and a new evening dose
(5 mg as opposed to no dose) during the study relative to
their pre-study MPH daily treatment. However, in the cur-
rent study, 91% of children were on once-a-day dosing
prior at prescreening, and it is therefore difficult to esti-
mate the effects of this factor on the current across-dose
comparison.BMC Psychiatry 2004, 4:28 http://www.biomedcentral.com/1471-244X/4/28
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Taken together, the existence of these confounding factors
and complications means that while these data provide an
initial indication of the relative efficacy of different doses
of CON and MCD at different points across the day they
should be treated with a certain degree of caution, and the
results should be confirmed in a study where subjects are
randomized to dose level rather than being assigned to it
on the basis of their pre-study MPH daily dose and plasma
levels of MPH are assessed simultaneously.
Conclusions
From the point of view of the practicing clinician the
results of this study further highlight the value of having
available different ER MPH formulations with different
expected plasma concentration vs. time profiles offering
different patterns of efficacy over different periods of the
day. Given the established dose-response relationship
between MPH and side effects, clinicians and parents may
wish to limit total daily MPH intake as far as possible
while maintaining a tolerable level of efficacy over the day
as a whole and/or targeting a particularly important
period of the day for a particular patient. This head-to-
head study makes a first step towards providing the sys-
tematic evidence base on which to make such decisions.
Competing interests
EJB and DC are consultant for and/or have received sup-
port from Celltech, McNeil, Jannsen Cilag and Eli Lilly.
JMS is a consultant for Celltech, McNeil and Eli Lilly. SJH
and HHD are employees of Celltech Americas, Inc.
Authors' contributions
JMS, DC, SJH and EJB participated in the design of this
post-hoc analysis while EJB performed the statistical anal-
ysis. HHD and EJB prepared the manuscript. All authors
contributed discussion and read and approved the final
manuscript.
Acknowledgements
This study was funded by Celltech Pharmaceuticals, Inc.
References
1. Goldman LS, Genel M, Bezman RJ, Slanetz PJ, for the Council on Sci-
entific Affairs, American Medical Association: Diagnosis and treat-
ment of attention-deficit/hyperactivity disorder in children
and adolescents. JAMA 1998, 279(14):1100-1107.
2. Mannuzza S, Klein RG: Long-term prognosis in attention deficit/
hyperactivity disorder.  Child Adolesc Psychiatr Clin N Am 2000,
9(3):711-726.
3. American Academy of Pediatrics, Subcommittee on Attention-Defi-
cit/Hyperactivity Disorder, Committee on Quality Improvement:
Clinical practice guideline: Treatment of the school-aged
child with Attention-Defecit/Hyperactivity Disorder. Pediat-
rics 2001, 108(4):1033-1044.
4. Greenhill LL, Perel JM, Rudolf G, Feldman B, Curran S, Puig-Antich J,
Gardner R: Correlations between motor persistence and
plasma levels of methylphenidate-treated boys with ADHD.
Int J Neuropsychopharmacol 2001, 4:207-215.
5. Horrigan JP, Kohli RR: The impact of dosing frequency on psy-
chostimulant compliance in ADHD. Presented at the 42nd Annual
New Clinical Drug Evaluation Unit (NCDEU) meeting: Boca Raton  [http:/
/www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu2056.cfm]. 10–13
June 2002
6. Pelham WE, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Milich R, Moorer
S: Sustained release and standard methylphenidate effects
on cognitive and social behavior in children with ADHD. Pedi-
atrics 1987, 80(4):491-501.
7. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, linde-
mulder E, Wigal S: Development of a new once-daily formula-
tion of methylphenidate for the treatment of Attention-
Deficit/Hyperactivity Disorder: Proof of concept and proof
of product studies. Arch Gen Psychiatry 2003, 60:204-211.
8. Wigal SB, Sanchez DY, DeCory HH, D'Imperio JM, Swanson JM:
Selection of the optimal dose ratio for a controlled-delivery
formulation of methylphenidate. J Appl Res 2003, 3(1):1-18.
9. Swanson JM, Lerner M, Wigal T, Steinhoff L, Greenhill L, Posner K,
Freid J, Wigal S: The use of a laboratory school protocol to
evaluate concepts about efficacy and side effects of new for-
mulations of stimulant medications.  J Atten Disord 2002,
6(Suppl 1):S73-S88.
10. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo
D, Atkins M, McBurnett K, Bukstein O, August J: Randomized, con-
trolled trial of OROS Methylphenidate once a day in children
with attention-deficit/hyperactivity disorder.  Pediatrics 2001,
108(4):883-892.
11. Greenhill LL, Findling RL, Swanson JM, the MPH MR ADHD Study
Group: A double-blind, placebo-controlled study of modified-
release methylphenidate in children with Attention-Deficit/
Hyperactivity Disorder. Pediatrics 2002, 109(3):E39.
12. Swanson JM., Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Bied-
erman J, Kollins S, Nguyen AS, DeCory HH, Hirshey Dirksen SJ,
Hatch SJ, the COMACS Study Group: Comparison of once-daily
extended-release methylphenidate formulations in children
with Attention-Deficit/Hyperactivity Disorder in the labora-
tory school (the Comacs study). Pediatrics 2004, 113:e206-e216.
13. Gonzalez MA, Pentikis HS, Andrl N, Benedict MF, DeCory HH, Hir-
shey-Dirksen SJ, Hatch SJ: Methylphenidate bioavailability from
two extended-release formulations.  Int J Clin Pharmacol Ther
2002, 40(4):175-184.
14. Gualtieri CT, Wargin W, Kanoy R, Patrick K, Shen CD, Youngblood
W, Mueller RA, Breese GR: Clinical studies of methylphenidate
serum levels in children and adults. J Am Acad Child Psychiatry
1982, 21:19-26.
15. Patrick KS, Mueller RA, Gualtieri CT, Breese GR: Pharmacokinet-
ics and actions of methylphenidate. In: Meltzer HY: Psychophar-
macology: The Third Generation of Progress Raven Press, New York;
1987:1387-1395. 
16. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA,
Kraemer G, Breese GR: Pharmacokinetics of methylphenidate
in man, rat, and monkey. J Pharmacol Exp Ther 1983, 226:382-386.
17. Swanson J, Wigal S, Greenhill L, Browne R, Waslick B, Lerner M, Wil-
liams L, Flynn D, Agler D, Crowley K, Fineberg E, Regino R, Baren M,
Cantwell D: Objective and subjective measures of the phar-
macodynamic effects of Adderall in the treatment of chil-
dren with ADHD in a controlled laboratory classroom
setting. Psychopharmacol Bull 1998, 34(1):55-60.
18. Wigal SB, Gupta S, Guinta D, Swanson JM: Reliability and validity
of the SKAMP rating scale in a laboratory school setting. Psy-
chopharmacol Bull 1998, 34:47-53.
19. Swanson JM, Volkow ND: Pharmacokinetic and pharmacody-
namic properties of stimulants: implications for the design of
new treatments for ADHD. Behav Brain Res 2002, 130:73-78.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-244X/4/28/pre
pub